Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
Posted on February 19, 2013 at 09:21 AM EST
Perrigo Company (Nasdaq: PRGO ) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone gel 1.62% and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing. On February 15, 2013, the